Compare Schwab US Large Cap Growth ETF (SCHG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs Smith & Nephew plc — how do they compare? Schwab US Large Cap Growth ETF trades at $34.24, while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while Schwab US Large Cap Growth ETF pays none, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SCHG | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $35.30 | $38.70 |
52-Week Low | $28.10 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
